If You Invested in Intra-Cellular Therapies Inc. (ITCI)
See the ITCI overviewWhat $1,000 or $10,000 in ITCI Was Worth at Its Last Close
Real historical value by amount invested and how long before the last close| If you invested | 1 year before | 5 years before | 10 years before | Since Nov 19, 2015 |
|---|---|---|---|---|
| $1,000 | $1,932 +93% | $9,120 +812% | — | $2,558 +156% |
| $10,000 | $19,316 +93% | $91,196 +812% | — | $25,576 +156% |
Based on real historical closing prices adjusted for stock splits, without dividends, through 2025-04-01. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for ITCI$1,000 Investment Over Time
ITCI vs S&P 500Year-by-Year Returns
ITCI annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2015Nov 19 to Dec 31 | $51.56 | $53.79 | +4.3% | +4.3% |
| 2016 | $53.79 | $15.09 | -71.9% | -70.7% |
| 2017 | $15.09 | $14.48 | -4.0% | -71.9% |
| 2018 | $14.48 | $11.39 | -21.3% | -77.9% |
| 2019 | $11.39 | $34.31 | +201.2% | -33.5% |
| 2020 | $34.31 | $31.80 | -7.3% | -38.3% |
| 2021 | $31.80 | $52.34 | +64.6% | +1.5% |
| 2022 | $52.34 | $52.92 | +1.1% | +2.6% |
| 2023 | $52.92 | $71.62 | +35.3% | +38.9% |
| 2024 | $71.62 | $83.52 | +16.6% | +62.0% |
| 2025Dec 31, 2024 to Apr 1 | $83.52 | $131.87 | +57.9% | +155.8% |
About Intra-Cellular Therapies Inc.
NASDAQ
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) is a biopharmaceutical company in the pharmaceutical preparation manufacturing industry. According to company disclosures, Intra-Cellular Therapies is focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The company states that it is founded on Nobel Prize-winning research that helps explain how therapies affect the inner workings of cells, and it applies this intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases.
Core business and therapeutic focus
Intra-Cellular Therapies describes itself as a CNS-focused biopharmaceutical company. Its business centers on researching, developing, and commercializing medicines that target psychiatric and neurologic conditions. The company highlights that its work is grounded in Nobel Prize-winning science related to intracellular signaling, and it uses this scientific foundation to design and advance drug candidates intended to address serious mental health and neurologic disorders.
A key commercial product for Intra-Cellular Therapies is CAPLYTA (lumateperone). Company communications state that CAPLYTA 42 mg is an oral, once-daily atypical antipsychotic approved in adults for the treatment of schizophrenia and for the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. The company notes that while the mechanism of action of CAPLYTA is unknown, its efficacy could be mediated through antagonist activity at central serotonin 5‑HT2A receptors and postsynaptic antagonist activity at central dopamine D2 receptors.
Research and development programs
Intra-Cellular Therapies reports that it is advancing a pipeline of CNS-focused programs. Lumateperone, the active ingredient in CAPLYTA, is being studied for additional indications beyond its approved uses. Company updates state that lumateperone is being evaluated as an adjunctive treatment for major depressive disorder (MDD) in adults. Two positive Phase 3 global, double-blind, placebo-controlled studies (Studies 501 and 502) in patients with MDD who had an inadequate response to ongoing antidepressant therapy form the basis of a supplemental New Drug Application (sNDA) submitted to the U.S. Food and Drug Administration (FDA) for this adjunctive MDD indication.
The company has also described additional lumateperone clinical programs, including studies in bipolar disorder and schizophrenia populations and pediatric programs. According to its updates, lumateperone is being studied in bipolar I disorder with manic or mixed episodes, in pediatric patients with bipolar depression and schizophrenia, and in pediatric patients for the treatment of irritability associated with autism spectrum disorder. Intra-Cellular Therapies also reports that lumateperone is being evaluated in adults for the acute treatment of manic or mixed episodes associated with bipolar I disorder and in long-term safety studies.
Beyond lumateperone, Intra-Cellular Therapies highlights several other pipeline programs. The ITI-1284-ODT-SL program is being studied in Phase 2 clinical trials in patients with generalized anxiety disorder (GAD), both as adjunctive therapy to approved GAD medications and as monotherapy, and in patients with psychosis associated with Alzheimer’s disease and in agitation associated with Alzheimer’s disease. The company also references a phosphodiesterase type I (PDE1) inhibitor program, including lenrispodun (ITI-214) in a Phase 2 study in Parkinson’s disease and ITI-1020 in oncology indications. In addition, Intra-Cellular Therapies describes an ITI-1500 non-hallucinogenic neuroplastogen program, with ITI-1549 advancing through investigational new drug (IND) enabling studies.
Commercial product: CAPLYTA (lumateperone)
Company materials identify CAPLYTA as a central product. CAPLYTA is described as an oral, once-daily atypical antipsychotic available in 10.5 mg, 21 mg, and 42 mg capsules. It is indicated in adults for the treatment of schizophrenia and for depressive episodes associated with bipolar I or II disorder as monotherapy and as adjunctive therapy with lithium or valproate. Intra-Cellular Therapies reports that CAPLYTA’s clinical data show efficacy in these indications and that its safety and tolerability profile has been characterized in multiple studies, including short-term and maintenance trials.
Intra-Cellular Therapies has reported financial results that reflect net product sales of CAPLYTA and associated operating expenses. The company attributes increases in selling, general and administrative expenses to commercialization, marketing, and infrastructure costs, and increases in research and development expenses to lumateperone and non-lumateperone project costs, including the ITI‑1284, ITI‑214, and ITI‑1500 programs.
Corporate developments and pending acquisition
Intra-Cellular Therapies has announced that it entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies. According to the joint announcement, Johnson & Johnson and Intra-Cellular Therapies agreed on a cash transaction in which Johnson & Johnson will acquire the company for a stated per-share price and total equity value. The companies state that, following completion of the transaction and subject to regulatory approvals, stockholder approval, and other customary closing conditions, Intra-Cellular Therapies’ common stock will no longer be listed for trading on the Nasdaq Global Select Market.
Under this agreement, Johnson & Johnson will add CAPLYTA (lumateperone) and Intra-Cellular Therapies’ pipeline programs, including ITI-1284 and PDE1 inhibitors, to its Innovative Medicine business. The transaction is described as part of Johnson & Johnson’s strategy to strengthen its neuroscience portfolio. Until the transaction closes, Intra-Cellular Therapies continues to be described as a Nasdaq-listed biopharmaceutical company operating under the symbol ITCI.
Intellectual property and legal matters
Intra-Cellular Therapies has disclosed patent litigation related to CAPLYTA. The company announced a settlement agreement with Sandoz Inc. resolving litigation that arose from Sandoz’s submission of an Abbreviated New Drug Application (ANDA) seeking approval to market a generic equivalent of CAPLYTA in the United States. Under the settlement, Intra-Cellular Therapies states that Sandoz is permitted to begin selling generic versions of CAPLYTA on a specified future date or earlier under certain circumstances. The company notes that similar patent litigation with other parties remains pending.
Scientific foundation and therapeutic areas
Across its public communications, Intra-Cellular Therapies emphasizes that it is founded on Nobel Prize-winning research into intracellular mechanisms. The company explains that this research underpins its understanding of how therapies affect cellular processes in the body and guides the design of its CNS-focused drug candidates. Its stated goal is to develop treatments for complex psychiatric and neurologic diseases, including schizophrenia, bipolar depression, major depressive disorder, generalized anxiety disorder, Alzheimer’s disease-related psychosis and agitation, Parkinson’s disease, and oncology indications associated with its PDE1 program.
Through CAPLYTA and its pipeline, Intra-Cellular Therapies positions itself as a developer and commercializer of CNS therapeutics that are informed by intracellular biology. Its disclosures highlight ongoing late-stage clinical trials, supplemental regulatory submissions, and collaborations with regulators and scientific communities through conference presentations and data releases.
ITCI stock and sector classification
ITCI is the ticker symbol for Intra-Cellular Therapies on the Nasdaq Global Select Market. Within broad industry classifications, the company is associated with pharmaceutical preparation manufacturing and the manufacturing sector, with a specific focus on biopharmaceutical research and commercialization in central nervous system disorders.
Frequently Asked Questions
Intra-Cellular Therapies Inc. investment returns
How much was $1,000 invested in Intra-Cellular Therapies Inc. worth at its last close?
If you invested $1,000 in Intra-Cellular Therapies Inc. (ITCI) 5 years before its last close, on 2020-04-01, your investment was worth $9,120 on 2025-04-01, a +812.0% price return without dividends, growing at a compounded rate of 55.6% per year (CAGR).
Has Intra-Cellular Therapies Inc. outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare ITCI performance over available time periods.
What is Intra-Cellular Therapies Inc.'s average annual return?
The compound annual growth rate (CAGR) of ITCI’s share price over the 5 years to Apr 1, 2025 is 55.6%, without dividends. Individual years vary a great deal, and ITCI’s best recent full year was 2019 (+201.2%) while the worst was 2016 (-71.9%).
For informational and educational purposes only, not investment advice.